StockData
Virax Biolabs Group Ltd logo

Virax Biolabs Group Ltd (VRAX) stock

VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30
$0.38−0.05 (-11.40%)

Close on Nov 19, 2026Market cap $220.68KP/E –Yield –

Virax Biolabs free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2026 it was -$4.88M.

Annual free cash flow

PeriodPeriod endValueChange
FY2026Mar 31, 2026-$4.88M–
FY2025Mar 31, 2025-$5.17M–
FY2024Mar 31, 2024-$7.35M–

More Virax Biolabs figures

See a number that looks wrong?